Phase 2 N=46 A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
Lupus Nephritis
Primary: Number of Participants With Adverse Events (AEs) — 14; 15; 15 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 Lidocaine for Oxaliplatin-induced Neuropathy
Neuropathy, Painful · Chemotherapy-induced Peripheral Neuropathy · Colorectal Cancer
Primary: Area Under the Curve (AUC) of Intensity of Oxaliplatin-induced Cold Pain/Unpleasantness vs Time — 16.4; 9.5; 33.1; 25.4 score on a scale*days — p=0.318
Phase 2 N=28 Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation
Breast Cancer
Primary: Feasibility for a Larger Trial — 42; 28; 28 Participants
Phase 2 N=806 Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
Severe Acute Respiratory Syndrome
Primary: Part 1: Percentage of Participants Alive and Free of Respiratory Failure at Day 28 — 67; 71 Percentage of participants — p=0.0456
Phase 2 N=44 Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
Waldenström's Macroglobulinemia (WM)
Primary: Major Response Rate (MRR) as Assessed by the Independent Review Committee — 69.8 Percentage of participants — p=<0.0001
Phase 2 N=289 An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Prostatic Neoplasms
Primary: Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation — 34.2…
Phase 2 N=42 Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis
Axial Spondyloarthritis
Primary: The Proportion of Subjects Who Achieved ASAS20 Clinical Response — 3; 14 Participants
Phase 2 N=35 Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Local Progression-free Survival (LPFS) — 22.30801 months
Phase 2 N=20 Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans
Type 2 Diabetes Mellitus · Insulin Resistance
Primary: Peripheral Insulin Sensitivity (RD) Measured by the Change in Glucose Rates of Disappearance With Resveratrol or Placebo at Baseline and at 4 Weeks. — 6.573; 7.272…
Phase 2 N=230 Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
Breast Carcinoma · Cervical Carcinoma · Ovarian Carcinoma
Primary: Change From Baseline at 9 Weeks in the Desire Subscore of the Female Sexual Function Index ("Sexual Desire") — 0.64; 0.60; 0.62 units on a scale — p=0.46
Phase 2 N=1,073 Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
Hemorrhagic Fever, Ebola
Primary: Number of Participants With Adverse Events (Day 29) — 96; 17; 68; 17 Participants
Phase 2 N=40 Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.
Anemia · Renal Insufficiency, Chronic
Primary: Change in Hemoglobin (Hb) Concentration Between the Baseline and the Evaluation Period for Each Patient — 11.05; 0.48 grams/deciliter (g/dL)
Phase 2 N=56 IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients
Pulmonary Arterial Hypertension · Iron Deficiency
Primary: Change in Exercise Capacity - Endurance — 315.44; 302.89 Seconds — p=0.6039
Phase 2 N=83 Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
COVID-19 Pneumonia · Acute Lung Injury · ARDS
Primary: Number of Subjects Alive and Free of Respiratory Failure — 26; 20 Participants — p=0.0440
Phase 2 N=392 Phase 2 Study of TD-9855 to Treat Fibromyalgia
Fibromyalgia
Primary: Percentage Change in Pain Score Based on the Mean of the Last 7 Daily Pain Numeric Rating Scale (NRS) Scores From the Daily Pain Diaries — -0.9; -1.2; -1.4 percentage…